A Multicentre, Randomised, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Sirukumab in the Treatment of Giant Cell Arteritis

ConclusionsAlthough data were limited due to early termination and shortened treatment duration, sirukumab treatment resulted in numerically lower proportions of patients with flare by week 52 versus placebo, with no unexpected safety findings.Trial RegistrationClinicaltrials.gov: NCT02531633.
Source: Rheumatology and Therapy - Category: Rheumatology Source Type: research